Marques Ana Rita, Teixeira Elsa, Diamond Joana, Correia Helena, Santos Sidónia, Neto Lara, Ribeiro Manuel, Miranda Ana, Passos-Coelho José Luís
Centro de Investigação de Patobiologia Molecular, Instituto Português de Oncologia de Francisco Gentil, Rua Professor Lima Basto, Lisboa Codex, Portugal.
Breast Cancer Res Treat. 2009 Mar;114(2):223-32. doi: 10.1007/s10549-008-0002-9. Epub 2008 Apr 13.
Human mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence.
Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included.
The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; P = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 +/- 0.22 and 0.13 +/- 013; P = 0.29). Furthermore, there was no difference in disease-free (P = 0.63) or overall survival (P = 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence.
There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence.
人乳腺珠蛋白（hMAM）mRNA是乳腺癌细胞的一种敏感且特异的标志物。我们评估了非转移性乳腺癌患者连续外周血样本中hMAM mRNA检测能否预测疾病复发。
计划接受辅助或新辅助化疗的患者符合条件。连续采集血样长达5年，首次在（新）辅助化疗前采集。通过逆转录聚合酶链反应（RT-PCR）分析hMAM基因表达。在健康志愿者的血样中评估特异性。共纳入321例患者。
化疗前hMAM阳性样本的发生率在后来发生癌症复发的患者（22.4%）和无疾病复发的患者（17.9%；P = 0.46）中相似。同样，两组随访阳性样本的平均数量相似（0.15 +/- 0.22和0.13 +/- 0.13；P = 0.29）。此外，基线样本为阳性和阴性的患者之间，以及随访样本始终为hMAM阴性和至少有一个阳性样本的患者之间，无病生存期（P = 0.63）或总生存期（P = 0.57）没有差异。多变量生存分析证实，（新）辅助化疗前后hMAM mRNA检测不能预测复发。
没有证据表明诊断时或随访期间检测hMAM mRNA可预测乳腺癌复发。
